Search

Biological rhythms may influence drug response (chronopharmacology) and some chronopharmacological studies have underlined the influence of time of day on drug pharmacodynamics and pharmacokinetics. The aim of the present review is to underline how biological rhythms may interfere with drug kinetics and to try to underline when, how, and why taking into account the moment of administration of a drug. Many physiological factors, possibly implicated in different steps of the fate of drugs in the organism (e.g., absorption, distribution, metabolism, and elimination) vary along the 24 h scale. Taking into account biological rhythms in kinetic studies, should be indicated when the concerned drug will be used in a chronobiological disease (e.g., asthma, cancer, depression, hypertension, gastrointestinal diseases, rheumatisms), etc. In case of a drug characterised by a high inter- and intra-variability, a narrow therapeutic range or when the drug will be further used following a once-a-day formulation. It is of importance to rigorously control factors which are known to influence pharmacokinetic processes in chronokinetic studies. Time of day has to be regarded as an additional variable to influence the kinetics of a drug., ((Copyright) 2008 Wiley-Liss, Inc.)

We investigated lithium-induced changes in norepinephrine (NE) catabolism. NE and its major metabolites 3-methoxy-4-hydroxyphenylglycol (MHPG) and 3,4-dihydroxyphenyl glycol (DHPG), ions such as lithium (Li(+)), magnesium (Mg(2+)), and potassium (K(+)) were measured in rat plasma and cerebral cortex using an HPLC method with electrochemical detection for amines. The results obtained with a group of rats treated by lithium chloride (2 mmol/kg/IP) were compared with a control group receiving sodium chloride (2 mmol/kg/IP). Animals were killed at different times over a period of six hours in the morning following salt administration to minimize possible chronobiological effects. There are two pathways leading to MHPG formation: way A, without DHPG, and way B, with DHPG. In plasma and cerebral cortex of lithium treated rats, way A catabolism seems to be preferential. Lithium increases Mg(2+) and K(+) plasma levels. These results suggest that lithium may increase inactivation of NE and decrease NE available for adrenergic receptors.

An assay was developed to quantify norepinephrine (NE) and its metabolites (MHPG and DHPG) by high-performance liquid chromatography with electrochemical detection method (HPLC-ECD) in brain tissue and plasma of rats treated by LiCl. Separation on C(18) column was obtained by a mobile phase consisting of 4.5% methanol in buffer (0.1 M sodium acetate, 0.2 M citric acid) containing 0.2 mM ethylenediaminetetraacetic acid disodium salt (EDTA Na(2)) and 0.4 mM sodium octylsulfate, operated at a flow rate of 0.8 ml/min. A potential of +0.78 V was applied across the working and reference electrodes of the detector. The precision was in the range 2.88-4.35% for NE, 5.94-11.0% for MHPG and 1.97-4.40% for DHPG. Accuracy was 98.8-99.3% for NE, 97.4-100% for MHPG and 96.1-101% for DHPG. The limit of detection was 0.6 ng/ml for NE, 0.5 ng/ml for MHPG and 0.2 ng/ml for DHPG. The linearity is over the range 20-60 ng/ml for NE, 7-23 ng/ml for MHPG and 6-20 ng/ml for DHPG. The assay has been applied successfully to measure simultaneously cortex and plasmas concentrations of these three catecholamines in rats.

Background: The pharmacokinetic profile of local anaesthetics is influenced by the mode of administration. We sought to compare the pharmacokinetics of two doses of ropivacaine after fascia iliaca compartment (FIC) block in children., Methods: In this prospective, double-blind study, children received an FIC block as a part of their anaesthetic management during elective orthopaedic surgery on the thigh. They were randomized to receive ropivacaine 0.7 ml x kg(-1) using either a 0.375% or 0.5% solution. Venous blood samples were drawn up to 6 h after injection. Plasma concentrations of ropivacaine were measured by gas-liquid chromatography., Results: Six children (10.2 (range 5-15) yr, 35.6 (sd 10) kg were included. FIC block provided satisfactory peroperative pain relief. No signs of toxicity were observed, but high maximal plasma concentrations (C(max) 4.33-5.6 microg ml(-1)), were observed for three of four patients in the ropivacaine 0.5% group. The two patients in the 0.375% group showed values within the safe range (C(max) 0.66 and 0.98 microg ml(-1) respectively). Even though no toxic effects were observed, these results led us to discontinue the study., Conclusions: The administration of ropivacaine 3.5 mg x kg(-1) can be associated with sustained high plasma concentrations of ropivacaine, outside the tolerable range. In view of these results, we recommend the use of lower ropivacaine dosage during FIC block in children.

The present work aims to document, in a previously described animal model of Parkinson (double bilateral striatal injection of 6-OHDA), the possible modifications of circadian markers rhythms i.e. temperature (T), heart rate (H) and locomotor activity (A) registered continuously by telemetry, in order to evaluate a possible perturbation of the circadian rythmicity. H, T and A were measured by radiotelemetry after surgical implantation of the transmitters (Data Sciences). After a recovery period, the study was divided into a control period (C) for baseline measurements of T, H and A daily rhythms. Then, the stereotaxic 6-OHDA striatal lesion was done to a group of 4 rats while the control rats were injected into striata with saline; a second period of four registration weeks was observed [D 1-7 (W1), D 8-14 (W2), D 15-21 (W3), D 22-28 (W4)]. Finally, at the end of this period the seven rats were decapited in order to determine their striatal dopamine (DA) content. Our data document that the circadian rhythms of H, T and A were differently affected according to time. Thus, a temporary loss of circadian periodicity was observed particularly for heart rate. 6-OHDA-induced modifications of H, T and A circadian rhythm characteristics were also observed: a significant decrease of the mesor was observed for the three rhythms as well as a phase advance. Concerning the amplitude of these rhythms, only H was significantly decreased. These perturbations were observed during the four weeks following the intervention, never reaching the initial control levels. Such observed perturbations would supply a basis for the future study of the chronopharmacology of antiparkinsonian drugs.

The aim of this study was to compare morning and evening repeated nicotine administration on the circadian rhythms of heart rate (H), body temperature (T) and locomotor activity (A) in unrestrained rats by using implanted radio-telemetry transmitters. The study was divided into three 7-day periods: a control period (P1), a treatment period (P2) and a recovery period (P3). During P2, four rats received nicotine (1mg.kg(-1)) subcutaneously at 09.00 h and four rats received nicotine in the same conditions at 21.00 h. For P1, P2 and P3, a power spectrum analysis was applied in order to determine the dominant period of rhythmicity. If H, T and A circadian rhythms were detected, the characteristics of these rhythms were determined by cosinor analysis, expressed as means+/-SEM and compared by ANOVA. Our results indicated: (1) a lack of detection of A circadian rhythm during P2 for the morning group while H and T circadian rhythms were detected for the morning and evening group whatever the period. (2) alterations of mesors, amplitudes and acrophases of H and T circadian rhythms for the morning and evening group during P2 and alterations of mesor, amplitude and acrophase of A circadian rhythm for the evening group. Furthermore these alterations were significantly different for the morning and evening group during P2. These results showed that the time of administration of nicotine differently affect H, T and A rhythms. The authors suggest that these effects can be mediated by central cholinergic and/or monoaminergic mechanisms.

Using radiotelemetry, this study aimed to evaluate the influence of tobacco smoke on heart rate (H), body temperature (T) and locomotor activity (A) daily rhythms in rats. The tobacco smoke intoxication was produced with a smoking apparatus. H, T, and A data were captured by radiotelemetry. The study was divided into three periods: a 1-week control period (P1), a 1-week stress period (P2), in order to evaluate the stress induced by the animals' restraint in the smoking apparatus, and a 1-week daily tobacco smoke intoxication period (P3). For P1, P2, and P3, a power spectrum analysis was applied in order to determine the dominant period of rhythmicity. Then, characteristics of the rhythms were determined by cosinor analysis. Statistical comparisons were done by ANOVA. Power spectrum analysis showed that neither stress nor tobacco suppressed the daily rhythmicity. Cosinor revealed some modifications: H amplitude was decreased during P2 and P3 with a greater reduction during P3, while T and A amplitudes were decreased during P2 and P3 without difference between P2 and P3. T acrophase was delayed during P2, while A acrophase was delayed during P2 and P3 without any difference between P2 and P3. These perturbations may reflect the effects of stress and tobacco on the suprachiasmatic nucleus by a dopaminergic mechanism.

The aim of this work was to determine the effects of different time of tobacco smoke exposure on pharmacokinetics of bupivacaine in mice. Mice were exposed to tobacco smoke during 4 days (group T4) or 8 days (group T8) using the Hamburg II smoking machine. Controls were exposed under the same experimental conditions but without tobacco smoke. Serum pharmacokinetic parameters, protein or erythrocyte binding of bupivacaine were measured on the 4th and 8th day of exposure. Furthermore the urines were kept during 24 hours and urine metabolite percentages were determined. After the short exposure (4 days), no differences between treated and control groups were reported in contrary to the longer exposure (8 days), where data showed a significantly increased metabolism and elimination of bupivacaine in the treated group compared to the controls. Our data indicate that tobacco smoke acts at different levels i.e. metabolism, elimination and binding of bupivacaine. Tobacco smoke exposure increases the metabolism of bupivacaine by activating the hydroxylation route and by inducing an important elimination of 3OH-bupivacaine. Besides, it increases the permeability of the cell membranes and facilitates the penetration of bupivacaine and desbutylbupivacaine in erythrocytes.

This study was designed to document possible changes in bupivacaine (B) local anaesthetic activity and pharmacokinetics in mice after a ketamine (K) injection. In the experiments, bupivacaine (8.25 mg.kg(-1)), was injected into the popliteal space of the right posterior limb: the local anaesthetic activity was assessed according to a sciatic nerve blockade method with three different doses (2, 10 and 40 mg/kg) of ketamine and the kinetics were studied after a 10 mg/kg dose. When ketamine was associated, the local anesthetic activity of bupivacaine was significantly enhanced as well as its elimination half-life. Significantly lower levels of the main metabolite, PPX, were observed, when ketamine was associated, suggesting a metabolic inhibition phenomenon. The ketamine-induced increase in the total anaesthetic effect of bupivacaine may thus be explained by kinetic modifications i.e. a possible inhibiting effect of ketamine on the metabolism of bupivacaine.

The aim of this work was to determine the effects of different exposure times to smoke on carboxyhemoglobin (HbCO) and hepatic enzymate activities in order to adapt a tobacco smoke intoxication model in mice. Mice were exposed to tobacco smoke for various durations of either 2 (group S2), 4 (group S4), 8 (group S8), or 31 days (group S31) using the Hamburg II machine. Controls (nonexposed animals) were used under the same experimental conditions. On the 2nd, 4th, 8th, and 31st day, mice were sacrificed by decapitation, and blood carboxyhemoglobin level and hepatic enzymate activities catalysed by CYP 450 families were measured. Our data with regard to the exposed group indicated first that HbCO was significantly increased after 4 or 8 days of exposure and decreased after 31 days compared to controls (where HbCO was constant for the duration of the 31 days) and second, the enzymate activities were significantly higher during the period of exposure. In conclusion, a 4- and 8-day exposure period with eight cigarettes per day seems to be the model of tobacco smoke intoxication in mice to be chosen.

Chronopharmacology studies the influence of time of administration of drugs. Numerous studies have report on the influence of time of administration on acute toxicity of drugs. Qualitative and quantitative responses of the organism to drugs have been described in different areas such as anaesthesiology, cardiology, oncology, endocrinology, gastroenterology, obstetrics, neurology, pneumology, psychiatry, rheumatology... in animals and in men. Underlying mechanisms of such variations involve temporal variations of the mode of action of the drug i.e. at the receptor level or temporal modifications of the kinetics of the drug. Absorption, distribution and drug protein binding, metabolism and elimination vary according to the moment of administration of the drug. Chronotherapy consists on the choice of the moment of administration of a drug in order to minimise its side effects and/or to emphasize its therapeutic effects.

An HPLC method for the simultaneous determination of both caffeine and theophylline in human plasma is described, using a reversed-phase chromatography column, heated by a thermostatic oven at 35 degrees C, with UV detection and isocratic elution. The linearity and reproducibility of the method are verified. For the two drugs, the limit of detection is 0.1 microgram ml-1. This analytical method is rapid and reliable and allows routine controls of therapeutic levels of theophylline and caffeine, especially in premature infants where the volume of plasma samples is very small.

The influence of four potassium channel agonists i.e. diazoxide (D), levcromakalim (L), nicorandil (N) and pinacidil (P) on bupivacaine-induced acute toxicity was evaluated by measuring the convulsant activity, the time of latency to convulse and the mortality rate. Four different dosages (i.e. 0.1, 1, 10 and 100 mg/kg/i.p. for D, N and P and 0.01, 0.1, 1 and 5 mg/kg/i.p. for L) were injected to a total of 200 male NMRI adult mice: 16 groups of 10 mice each were previously treated by a single i.p. dose of each potassium channel agonist while controls (n = 40) received saline injection. Thus, 15 minutes later, all groups were injected with a 50 mg/kg/i.p. single dose of bupivacaine. The convulsant activity of bupivacaine was significantly modified by only high doses of L in a dose-dependent manner. Compared to the controls, the period of latency was significantly increased for most of the doses of P, N, D and L in a dose dependent manner for L and P. The anesthetic-induced mortality (47.5% for controls) was not significantly modified by D, but decreased by N and increased by high doses of L and P which is probably related to a delayed mortality.

This study was designed to document possible changes in bupivacaine and its main metabolite, des-butyl-bupivacaine (PPX) kinetics in mice after a single 5 mg/kg injection of diltiazem. After a single 20 mg/kg i.p. dose of bupivacaine, kinetic parameters of bupivacaine were not statistically different but the ratio AUC PPX/AUC bupivacaine was significantly lower when bupivacaine was associated with diltiazem: thus, it may indicate an influence of diltiazem on bupivacaine metabolism i.e. an inhibition. Diltiazem also seems to increase the free fraction of bupivacaine and thus to decrease the percentage of protein binding. These effects may contribute to the enhanced toxicity previously observed.

Chronopharmacokinetics deals with the study of the temporal changes in absorption, distribution, metabolism and elimination and thus takes into account the influence of time of administration on these different steps. In the last decade, numerous studies have been devoted to chronokinetics: recent advances will be reviewed in the first part. As representative examples, the main chronokinetic changes of anaesthetics, cardiovascular active drugs and antiinflammatory drugs in men are listed. Temporal changes can be involved at each step of the sequence of pharmacokinetic processes: temporal variations in drug absorption from the gastro-intestinal tract, in plasma protein binding and drug distribution, in drug metabolism (temporal variations in enzyme activity, hepatic blood flow) and in renal drug excretion may play a role. Thus, the time of administration of a drug is an important source of variation which must be taken into account in kinetic studies and particular methodological aspects of chronokinetics are needed. In a chronopharmacokinetic study many factors of variation must be controlled: factors related to the drug itself (influence of food, galenic formulation, drug interactions), subject related-factors (age, gender, pathology, posture, exercise, synchronization) and factors related to the conditions of the administration (single or repeated dosing, constant rate delivery, route of administration). In conclusion, there are some instances in which a chronokinetic study is needed: 1) when possible daily variations in pharmacokinetics may be responsible for time dependent variations in drug effects, 2) when drugs have a narrow therapeutic range, 3) when symptoms of a disease are clearly circadian phase-dependent (e.g. nocturnal asthma, angina pectoris, myocardial infarction, ulcer disease) 4) when drug plasma concentrations are well correlated to the therapeutic effect in case the latter is circadian phase-dependent. Variables influencing pharmacokinetics such as fasting, meals and meal times, galenic formulation, posture, activity-rest, have to be controlled according to the aim of the investigation. The main aim of chronokinetic studies is to control the time of administration which among others, can be responsible for variations of drug kinetics but also may explain chronopharmacological effects observed with certain drugs.

This study was designed to document possible changes in bupivacaine kinetics in mice after a single 1 mg/kg injection of flumazenil. After a single 20 mg/kg i.p. dose of bupivacaine, C max, Vd, Cl and AUC were not significantly modified by flumazenil; even if T max was shown to be significantly shorter when flumazenil was associated, bupivacaine bioavailability did not seem to be modified and thus may not be involved in the explanation of previously reported increasing bupivacaine-induced mortality by flumazenil.

The purpose of this study was to investigate the influence of calcium channel blockers on bupivacaine-induced acute toxicity. For each of the three tested calcium channel blockers (diltiazem, verapamil and bepridil) 6 groups of mice were treated by two different doses, i.e. 2 and 10 mg/kg/i.p., or an equal volume of saline for the control group (n = 20); 15 minutes later, all the animals were injected with a single 50 mg/kg/i.p. dose of bupivacaine. The convulsant activity, the time of latency to convulse and the mortality rate were assessed in each group. The local anesthetic-induced mortality was significantly increased by the three different calcium channel blockers. The convulsant activity of bupivacaine was not significantly modified but calcium channel blockers decreased the time of latency to obtain bupivacaine-induced convulsions; this effect was less pronounced with bepridil.

The purpose of this study was to investigate the influence of flumazenil on local anesthetic-induced acute toxicity. For each of the three tested anesthetics (etidocaine, mepivacaine and lidocaine) 6 groups of mice were treated by a single dose of flumazenil (0.125, 0.25, 0.5, 1 and 2 mg/kg), or an equal volume of saline, 15 minutes before the injection of the anesthetic (etidocaine: 50 mg/kg, mepivacaine: 110 mg/kg and lidocaine: 115 mg/kg). The convulsant activity, the time of latency to convulse and the mortality rate were assessed in each group. The local anesthetic-induced mortality was not significantly modified by flumazenil. The convulsant activity of lidocaine and mepivacaine was significantly increased by flumazenil but not for etidocaine. Also, increasing doses of flumazenil decreased the time of latency to obtain lidocaine-induced convulsions. This effect was not obtained with etidocaine or mepivacaine.

The aim of the study was to evaluate, in clinical conditions, the penetration of ciprofloxacin into bronchial secretions. Eight patients were included in the study. They presented with nosocomial pneumonia and were under controlled mechanical ventilation. Ciprofloxacin was given at a dose of 3 mg/kg over 30 min. Serial bronchial and blood samples were obtained over a 12 hour period on day 2 and 4. Ciprofloxacin was measured by HPLC. Serum peak levels were 2.95 +/- 1 mg/l on day 2, and 2.43 +/- 0.7 mg/l on day 4. Bronchial peak and through levels were 0.95 +/- 0.51 mg/l and 0.21 +/- 0.12 mg/l, respectively, on day 2, and 0.76 +/- 0.17 mg/l and 0.18 +/- 0.14 mg/l, respectively, on day 4. The ratio of bronchial/serum peak was 0.32 +/- 0.11 and 0.33 +/- 0.06 on day 2 and 4, respectively. The ratio of AUC 0-12 h in the bronchial secretions/AUC 0-12 h in the serum samples was 0.66 +/- 0.04 and 0.55 +/- 0.27 on day 2 and 4, respectively.

This study was designed to document possible changes in bupivacaine kinetics in serum and in heart and brain tissues induced by a pretreatment with diazepam in mice. When diazepam is associated with bupivacaine, elimination of bupivacaine from serum and cardiac tissues is decreased; statistical differences were not found in brain tissues.

The purpose of this study was to investigate the influence of flumazenil on bupivacaine-induced acute toxicity, 10 groups of mice were previously treated by a 1, 0.5, 0.25 and 0.125 mg/kg single dose of flumazenil or saline 15 minutes before an injection of bupivacaine (50 mg/kg: exp. 1 and 60 mg/kg: exp.2). The convulsant activity, the period of latency to convulse and the induced mortality were assessed in each group. The bupivacaine-induced mortality was increased by flumazenil. Also, the convulsant activity was increased by flumazenil and the period of latency to convulse was proportionally decreased with increasing doses of flumazenil for the two tested doses of bupivacaine.

The pharmacokinetics of ofloxacin was studied in 12 intensive care patients, 6 of whom being under mechanical ventilation. All patients had a creatinine clearance greater than 60 ml/min/1.73 m2 and they were given 3 mg/kg. IV ofloxacin within 30 mn, with a twice daily regimen for 7 days. Pharmacokinetic studies were performed on day 1 (D1) and 7 (D7). Between D1 and D7 a significant increase in T 1/2 beta, AUC and blood levels were observed together with a decrease in total body clearance. Creatinine clearance was not modified between D1 and D7 but ofloxacin renal clearance was considerably altered. Abnormalities in ofloxacin renal tubular secretion may account for the drug cumulation which was observed during repeated administration in intensive care patients.

Cyclic variations in circulating hormone levels and the associated physiological changes during the menstrual cycle may modify the pharmacokinetics of drugs. So gastric acidity or gastrointestinal motility variations may alter drug absorption; plasma protein concentration changes may also modify drug binding. Finally biotransformations and elimination may be changed during the menstrual cycle. The few studies on menstrual changes in pharmacokinetics are often conflicting and this factor needs to be better documented.

A comparative study of two antiemetic neuroleptics, metoclopramide and metopimazine, effects on the oestrus cycle of female rats has been done. These compounds were administered once daily for 21 consecutive days (1, 0,1, 0,01, 0,001 mg/kg/s.c.) on Wistar AFSPF rats, exhibiting regular four day cycles. Evolution of oestrus cycle was studied by daily vaginal smears. Our data show that metoclopramide does not influence oestrus cycle, while metopimazine suppress oestrus cycles, substituted for a permanent dioestrus. For the last compound, a statistically significant difference between treated and controls is demonstrated.

Circadian changes of total proteins erythrocyte sedimentation rate, IgA, IgG, IgM and 12 others blood compounds were documented in 40, 40-60 years old, hospitalized males without any inflammatory or hepatic disease. These patients were synchronized by diurnal activity and nocturnal rest, and each of them was submitted to 5 samples during a 24 hours scale (07.00, 13.00, 19.00, 01.00 and 07.00). We only detected C3, IgM and total proteins significant circadian rhythms (peak time in the diurnal period). When these data were analysed by mean-Cosinor, they revealed three groups of subjects: 16 patients with an acrophase at 17.00 +/- 3.00, 8 with an acrophase at 06.00 +/- 3.00 and 16 (third/group) with large differences in the acrophase values. Such heterogenous results are discussed.

The effects of joint treatment by sulpiride (1 mg . kg-1 S.C. pro die) and bromocriptine (3 mg . kg-1 S.C. pro die) on female rat estrous cycles were carried out on a group of ninety animals for a twenty-one days period. The results thus obtained show that: (i) bromocriptine alone does not disturb the estrous cycle, (ii) when given both with sulpiride, it prevents from this psycholeptic's estrous cycle blockade, (iii) finally, it leads to the regression of a blockade induced by an eight days sulpiride pretreatment. Therefore, it is likely that these two drugs act antagonistically at tuberoinfundibular dopaminergic receptors involved in the prolactin and gonadotropins release.

Time of drug administration may be responsible among other factors for nonlinearity in pharmacokinetics. More than a hundred studies have reported on chronokinetics. Absorption, distribution, metabolism and elimination rate of a drug depend on temporal variations: drug absorption processes vary with time of day even in fasting conditions. Temporal changes in membrane permeability may be involved in temporal variations of distribution such as in protein binding. Circadian variations of the metabolism of a drug may also depend on circadian changes of metabolizing enzymes activities or on blood flow variations in the concerned organs. Finally the elimination rate of drugs depends on timing of administration according to renal blood flow, glomerular filtration and pH variations. Such chronokinetic studies are needed for a better understanding of nonlinearity of kinetics and may explain, in part at least, chronopharmacological data.

Temporal changes in membrane permeability to bupivacaine (B), etidocaine (E) and mepivacaine (M) documented by their erythrocytic penetration were studied in mice. Temporal variations of B, E and M erythrocytic penetration were demonstrated with a maximum at 04.00 h for B (amplitude = 148%), 10.00 h for E (amplitude = 146%) and at 10.00 h for M (amplitude = 75%). Differences in the circadian pattern of erythrocytic penetration of B, E and M are discussed according to physicochemical properties of these three agents.

The influence of menstrual cycle on drug kinetics is not largely documented. Concerning theophylline it was of interest to investigate whether or not the kinetics of this drug is modified throughout the oestrous cycle. Though the kinetics of this drug was assessed in adult Wistar female rats at different stages of the oestrous cycle: proestrous (P), oestrous (O) and diestrus (D). Our preliminary data clearly indicate statistically significant differences (p less than 0.01) of theophylline kinetic parameters such as elimination half-life: 8.70 +/- 0.60 h (P), 4.61 +/- 0.16 h (O) and 5.01 +/- 0.85 h (D), area under concentration versus time curve (AUC): 214.61 +/- 3.58 micrograms.h/ml (P), 128.64 +/- 9.64 micrograms.h/ml (O) and 165.57 +/- 23.86 micrograms.h/ml (D). These results agree with clinical data reported on the influence of estroprogestative drugs on theophylline kinetics in women (higher elimination half-life and lower clearance). In order to explain some of our findings the possible variations of theophylline protein binding and metabolism throughout the oestrous cycle are under investigation.

For chronopharmacokinetic investigations on bupivacaine in mice we needed a gas liquid chromatographic (GLC) method with flame ionization detection, sufficiently sensitive, linear and precise: thus we describe in this paper a GLC method adapted from previous findings of Desh and al. A single extraction procedure involving methylene chloride was used with mepivacaine as internal standard. Under the conditions of the assay used, retention times were 3.3 minutes and 6.3 minutes for mepivacaine and bupivacaine, respectively. Repeatability and recovery of the method were good and standard calibration curves were linear in the concentration range studied. The assay described herein has been used to study single dose kinetics of bupivacaine in mice. The method herein described is more sensible and more rapid for the determination of bupivacaine than previous GLC methods.